Pregled bibliografske jedinice broj: 1139344
Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study
Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study // Psychopharmacology, 238 (2019), 5; 1303-1314 doi:10.1007/s00213-019-05303-2 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1139344 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Choline elevation in amygdala region at
recovery indicates longer survival without
depressive episode: a magnetic resonance
spectroscopy study
Autori
Henigsberg, Neven ; Savić, Aleksandar ; Radoš, Marko ; Radoš, Milan ; Šarac, Helena ; Šečić, Ana ; Bajs Janović, Maja ; Foro, Tamara ; Ozretić, David ; Erdeljić Turk, Viktorija ; Hrabač, Pero ; Kalember, Petra
Izvornik
Psychopharmacology (0033-3158) 238
(2019), 5;
1303-1314
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Depression ; Magnetic resonance spectroscopy ; Recurrence ; Antidepressants ; Therapy ; Recovery ; NAA ; Cho ; Glx
Sažetak
Rationale Depression, with variable longitudinal patterns, recurs in one third of patients.We lack useful predictors of its course/ outcome, and proton magnetic resonance spectroscopy (1H-MRS) of brain metabolites is an underused research modality in finding outcome correlates. Objectives To determine if brain metabolite levels/changes in the amygdala region observed early in the recovery phase indicate depression recurrence risk in patients receiving maintenance therapy. Methods Forty-eight patients on stable-dose antidepressant (AD) maintenance therapy were analyzed from recovery onset until (i) recurrence of depression or (ii) start ofAD discontinuation. Two 1H-MRS scans (6 months apart) were performed with a focus on amygdala at the beginning of recovery. N- acetylaspartate (NAA), choline-containing metabolites (Cho), and Glx (glutamine/glutamate and GABA) were evaluated with regard to time without recurrence, and risks were assessed by Cox proportional hazard modeling. Results Twenty patients had depression recurrence, and 23 patients reached AD discontinuation. General linear model repeated measures analysis displayed three-way interaction of measurement time, metabolite level, and recurrence on maintenance therapy, in a multivariate test, Wilks’ lambda = 0.857, F(2, 40) = 3.348, p = 0.045. Cho levels at the beginning of recovery and subsequent changes convey the highest risk for earlier recurrence. Patients experiencing higher amygdala Cho after recovery are at a significantly lower risk for depression recurrence (hazard ratio = 0.32 ; 95% confidence interval 0.13–0.77). Conclusion Cho levels/changes in the amygdala early in the recovery phase correlate with clinical outcome. In the absence of major NAA fluctuations, changes in Cho and Glx may suggest a shift towards reduction in (previously increased) glutamatergic neurotransmission. Investigation of a larger sample with greater sampling frequency is needed to confirm the possible predictive role of metabolite changes in the amygdala region early in the recovery phase.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Profili:
David Ozretić
(autor)
Helena Šarac
(autor)
Neven Henigsberg
(autor)
Aleksandar Savić
(autor)
Pero Hrabač
(autor)
Maja Bajs Janović
(autor)
Marko Radoš
(autor)
Milan Radoš
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE